Thus, Juric and coworkers discovered loss of PTEN in a patient with a PI3KCA-mutant breast cancer undergoing treatment with the PI3K inhibitor BYL719 and developing resistance to this drug [179]. Here, PIK3CA is linked to breast carcinoma.